Life Sciences
CIRM invests $10 million to build California Cell and Gene Therapy Manufacturing Network
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $10 million to…
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $10 million to five facilities as part of the first phase to build a California Cell and Gene Therapy Manufacturing Network.
The awards include:
| Application # | Program Title | Principal Investigator/Institution | Amount |
| INFR5-14663 | Laboratory for Cell and Gene Medicine: A partner in the California Cell and Gene Therapy Manufacturing Network | Steven Feldman — Stanford University | $2,000,000 |
| INFR5-14739 | Enhancing California’s Manufacturing of Leading-Edge Cell & Gene Therapies | Dawn Ward — University of California, Los Angeles | $2,000,000 |
| INFR5-14756 | Scalable Expansion for Stem Cell-Derived Therapies | Taby Ahsan — Beckman Research Institute of City of Hope | $1,998,174 |
| INFR5-14636 | A comprehensive biomanufacturing center solving bottlenecks in cell and gene therapy manufacturing to accelerate new therapies for California patients | Dhruv Sareen — Cedars-Sinai Medical Center | $2,000,000 |
| INFR5-14719 | Open Manufacturing Network for Cell and Gene Therapies | Brian Rudolph Shy — University of California, San Francisco | $1,999,933 |
The statewide network is designed to overcome manufacturing bottlenecks that have delayed or stalled development and approval of regenerative medicines.
“These awards are a critical first step in formation of the manufacturing network and will help California academic GMP manufacturing facilities raise the quality and competency of cell and gene therapy manufacturing across the state,” says CIRM Senior Director of Business Development & Alliance Management Dr. Shyam Patel. “Plus, these awards will also provide manufacturing career training opportunities for Californians, which align perfectly with CIRM’s mission.”
Phase one of the awards will fund California non-profit GMP manufacturing facilities for two years. Each facility will support in accelerating and de-risking the path to commercialization for cell and gene therapies, advancing industry standards and quality by design, and building a diverse and highly skilled manufacturing workforce in California.
Phase two of the awards will fund collaborative partnerships that will scale efforts from the first phase across the network.
To learn more about CIRM’s Infrastructure programs, including future funding opportunities, visit our website.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
